Click here to jump to the course page menu

Potential Risks and Contraindications of Vagal Interventions

Purpose: To support safe practice by outlining known risks, side effects, and contraindications across common vagal interventions. This page balances enthusiasm for vagal modulation with realistic cautions so practitioners and clients can make informed, ethical choices.

Scope

This page covers (a) surgically implanted Vagus Nerve Stimulation (VNS) systems; (b) non-invasive transcutaneous auricular VNS (taVNS); and (c) “vagal manoeuvres” or other approaches that influence vagal tone (e.g., breathwork, cold exposure). It is written for therapists and coaches; it is not a substitute for medical advice. Where uncertainty exists, default to medical referral.

General risk themes across vagal interventions

Bradycardia and hypotension: Excess parasympathetic drive can reduce heart rate and blood pressure, leading to dizziness, presyncope, or syncope. Those with conduction disease or on rate-limiting drugs are at higher risk.
Respiratory and laryngeal effects: Hoarseness, cough, throat discomfort, dyspnoea—especially with implanted VNS, but also reported (milder) with taVNS.
Dermatologic/neuropathic irritation: With taVNS, local skin irritation, tingling, headache, or ear discomfort are common and typically mild.
Neuropsychiatric considerations: Mood changes can occur (improvement or, rarely, worsening); careful monitoring is advised for depression and suicidality with implanted VNS per NICE.
Device interactions: Implanted stimulators can interact with diathermy, MRI settings, electrosurgery, and cardiac devices.

Modality-specific risks and contraindications

A) Surgically implanted VNS (for epilepsy or treatment-resistant depression)

Common side effects: Voice alteration/hoarseness, cough, throat pain, dyspnoea, dysphagia, headache, neck pain, and paraesthesiae during stimulation. These often diminish with parameter adjustment. NICE IPG679; FDA SSED; Ben-Menachem 2015.
Surgical risks: Infection, bleeding/haematoma, lead fracture or migration, device failure, pain at implant site. NICE committee notes.
Specific warnings: Do not use therapeutic diathermy in patients with implanted VNS (risk of serious injury/device damage). Evaluate for obstructive sleep apnoea; VNS may precipitate or worsen sleep apnoea in some patients. FDA SSED; FDA patient/physician labelling.
Psychiatric monitoring: NICE notes frequent, well-recognised side effects and limited efficacy evidence for depression; use only with special arrangements for governance, consent, and audit. NICE IPG679.

B) Transcutaneous auricular VNS (taVNS)

Typical adverse effects: Local skin irritation/erythema, tingling, headache, fatigue, transient insomnia, nasopharyngitis; serious events are rare in trials. Tan 2023 meta-analysis; Giraudier 2025 pooled analysis; Frontiers 2025 review.
Practical cautions: Avoid use over broken skin; stop if sustained dizziness, chest pain, or syncope occurs. Start with low intensity; avoid continuous high-duty cycles without clinical oversight.
Relative contraindications: Known arrhythmias or significant conduction disease; implanted pacemaker/ICD (seek cardiology advice); pregnancy (insufficient data); children—use only within research/clinical protocols.

C) “Vagal manoeuvres” and neck-adjacent techniques

Valsalva/cold-face (“diving reflex”): Generally safe in healthy adults, but can precipitate presyncope in those with orthostatic intolerance or on rate-limiting drugs.
Carotid sinus massage (CSM): Not a wellness technique; reserved for acute supraventricular tachycardia in monitored clinical settings. Contraindicated with carotid bruits, recent TIA/stroke/MI, or known carotid stenosis; risk of neurological complications. NEJM clinical review; ACC/AHA/HRS guideline; Europace 2024.

Medication and device interactions

Rate-limiting agents: Beta-blockers (e.g., propranolol), non-dihydropyridine calcium channel blockers (verapamil, diltiazem), certain antiarrhythmics, and digoxin—combined effects may increase risk of bradycardia or AV block; use added caution with any vagal-increasing technique.
Anticholinesterases (e.g., donepezil, rivastigmine): Can increase vagal tone and bradyarrhythmic risk.
Implanted devices: Implanted VNS can interact with diathermy, electrocautery, and MRI conditions and may require special perioperative management. FDA SSED.
Pacemakers/ICDs: taVNS is generally avoided unless electrophysiology review confirms safety for the specific device and parameters.

Populations requiring heightened caution

Known conduction disease, bradyarrhythmias, or significant structural heart disease.
Recent TIA/stroke, carotid artery disease, or carotid bruits: Avoid neck manipulation/CSM outside hospital settings. NEJM.
Obstructive sleep apnoea (OSA) or high OSA risk: Implanted VNS can unmask or worsen OSA; screen for symptoms. FDA labelling.
Pregnancy and postpartum: Insufficient safety data for taVNS—avoid unless within a clinical protocol.
Older adults with orthostatic hypotension or polypharmacy: Higher presyncope risk with strong vagal manoeuvres.
Active infection or skin disease at ear/electrode site (for taVNS).

Contraindication Summary (quick reference)

Intervention	Absolute contraindications	Relative cautions	Common side effects
Implanted VNS	Therapeutic diathermy. Inability to manage the device perioperatively. Active surgical site infection.	OSA/OSA risk. Arrhythmias. Device dependency (pacemaker/ICD)—specialist oversight. Pregnancy (insufficient depression-specific data).	Hoarseness. Cough. Throat pain. Dyspnoea. Dysphagia. Headache. Neck pain. Surgical complications
taVNS (auricular)	Severe peripheral vascular disease.	Arrhythmias. Pregnancy. Paediatrics. Migraine with brainstem aura.	Skin irritation. Tingling. Headache. Fatigue. Ear discomfort. Transient insomnia.
Valsalva / cold-face	Acute myocardial infarction. Recent TIA/stroke. Severe aortic stenosis	Orthostatic intolerance. Rate-limiting drugs. Dehydration.	Light-headedness. Transient visual dimming. Presyncope.
Carotid sinus massage (CSM)	Do not use outside clinical settings. Carotid bruits. Recent TIA/stroke/MI. Known carotid stenosis	Elderly with vascular disease.	Bradycardia. Hypotension. Neurological complications (rare but serious).

Key sources: NICE IPG679; FDA SSED; Ben-Menachem 2015; Tan 2023; Giraudier 2025; NEJM.

Pre-screening and monitoring checklist (for therapists/coaches)

Medical history screen: Heart rhythm issues, syncope, OSA, recent TIA/stroke/MI, vascular disease, pregnancy, implanted devices, dermatologic issues at ear.
Medication review: Beta-blockers, non-DHP calcium channel blockers, digoxin, antiarrhythmics, anticholinesterases; note polypharmacy and alcohol use.
Baseline vitals (if trained): Resting HR/BP; consider simple orthostatic check in presyncopal clients.
Start-low, go-slow: Gradual titration of taVNS intensity and duty cycle; avoid prolonged continuous sessions initially.
Explain “stop-criteria” to client: Stop immediately and seek care if chest pain, sustained dizziness/syncope, severe shortness of breath, new neurological symptoms, or persistent throat tightness occur.
Documentation: Record parameters, duration, site (left cymba conchae/tragus for taVNS), sensations, and after-effects.
Referral threshold: Any red flag, complex cardiac history, or implanted devices → GP/cardiology/neurology.

Suggested client advisory

Safety notice: Vagal stimulation can lower heart rate and blood pressure. Do not use if you have significant heart rhythm problems, a pacemaker/defibrillator (unless cleared by your specialist), a recent stroke or mini-stroke, or carotid artery disease. Stop immediately if you feel faint, develop chest pain, severe breathlessness, or new neurological symptoms, and seek urgent medical care. If you are pregnant or trying to conceive, consult your clinician before using vagal devices.

Book cover featured in Potential Risks and Contraindications of Vagal Interventions

Ethical and legal notes for non-medical practitioners

Informed consent: Provide balanced information, including limited evidence for some indications (e.g., depression with implanted VNS under NICE IPG679 special arrangements).
Scope of practice: Do not perform carotid sinus massage or any medical manoeuvre outside your training and in a clinical setting.
Adverse event reporting: Document and signpost to GP/ED as appropriate; report device-related issues to the manufacturer and relevant regulator (e.g., the MHRA Yellow Card Scheme in the UK).

Key References and Guidance

National Institute for Health and Care Excellence. (2020). Implanted vagus nerve stimulation for treatment-resistant depression (IPG679), NICE.
→ reviews the safety profile, side-effect burden, limited efficacy evidence, and governance requirements for implanted vagus nerve stimulation in treatment-resistant depression.
National Institute for Health and Care Excellence. (2020). Implanted vagus nerve stimulation for treatment-resistant depression (IPG679): Committee considerations, NICE.
→ details the committee’s evaluation of safety concerns, clinical and cost-effectiveness, evidence uncertainty, and the rationale for special governance arrangements.
U.S. Food and Drug Administration. (n.d.). Summary of Safety and Effectiveness Data (SSED): VNS Therapy System.
→ details the regulatory safety data for the VNS Therapy System, including warnings related to diathermy, obstructive sleep apnoea, device malfunction, and surgical risks.
U.S. Food and Drug Administration. (n.d.). Summary of safety and effectiveness data (SSED): VNS Therapy System, Supplement S207C.
→ updated regulatory safety data for the VNS Therapy System, including device performance, adverse events, labelling changes, and expanded clinical considerations.
Ben-Menachem, E. et al. (2015). Surgically implanted and non-invasive vagus nerve stimulation: A review of efficacy, safety and tolerability. European Journal of Neurology, 22(9), 1260–1268.
→ compares the efficacy, safety profile, and tolerability of surgically implanted and non-invasive vagus nerve stimulation across neurological and psychiatric indications.
Tan C. et al. (2023). The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Journal of Affective Disorders, 337, 37–49.
→ evaluates the clinical efficacy and safety of transcutaneous auricular vagus nerve stimulation in depressive disorder across randomised controlled trials.
Giraudier, M. et al. (2025). A pooled analysis of the side effects of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS). Frontiers in Human Neuroscience, 19, 1539416.
→ quantifies the frequency, type, and clinical relevance of adverse effects associated with non-invasive transcutaneous auricular vagus nerve stimulation across multiple controlled studies.
Matsuoka, M. et al. (2025, October 24). Transcutaneous auricular vagus nerve stimulation in healthy individuals, stroke, and Parkinson’s disease: A narrative review of safety, parameters, and efficacy. Frontiers in Physiology, 16, Article 1693907.
→ examines safety data, stimulation parameters, and reported effects of transcutaneous auricular vagus nerve stimulation (taVNS) across healthy subjects, stroke survivors, and people with Parkinson’s disease.
Pasquier, M. et al. (2017). Carotid sinus massage. New England Journal of Medicine, 377(15), e21. NEJM clinical review
→ demonstrates the correct technique, indications, and safety considerations for carotid sinus massage in the evaluation of supraventricular tachycardia.
Kusumoto, F. M. et al. (2019). 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. AHA Journal. Circulation, 140(8), e382–e482.
→ provides recommendations for diagnosing and managing bradycardia and cardiac conduction disorders, offering key safety standards for patients undergoing autonomic or neuromodulatory interventions.
de Lange, F. et al. (2024). Carotid sinus massage in clinical practice: The Six-Step-Method. EP Europace, 26(11), euae266. Europace 2024.
→ standardises the safe performance of carotid sinus massage using a structured six-step method for diagnostic evaluation of reflex syncope and arrhythmias.

Bottom line for safe practice

Screen all clients for cardiac rhythm disorders, vascular disease, implanted devices, pregnancy, sleep apnoea risk, and interacting medications.
Use non-invasive techniques with conservative parameters and gradual exposure.
Monitor for presyncope, emotional destabilisation, or respiratory discomfort.
Maintain clear stop-criteria, document all responses, and refer promptly when uncertainty or red flags arise.

The Vagus Nerve Index